The Science Behind Targeted Treatments and Immunotherapies for Malignant Melanoma

Format: This is a live, virtual event. Each morning’s content is split over three sessions of 30-40 minutes each. Elaine will be online throughout both mornings to interact with learners and answer questions in the live Q&A sessions that follow each presentation. Recordings of the presentations will be available online for 30 days after the live event.

Description: This morning Elaine provides an up-to-date overview of the science behind targeted treatments and immunotherapies for people with malignant melanoma. She begins with the gene mutations that cause melanoma and describes the biology of this disease and its relationship with the immune system. She then describes various treatment approaches, such as B-Raf and MEK inhibitors and immunotherapy with checkpoint inhibitors.

Elaine’s goal is to explain the science that underpins each treatment and to provide learners with a broad understanding of why treatments work well for some patients but not for others.

Audience: Ideal for pharmacists, research nurses, pharmaceutical companies, junior doctors or anyone who has been on one of Elaine’s other courses

Cost: £50

To book, contact: conferenceteam@rmh.nhs.uk
View a PDF of the programme